Epinephrine Market Growth Prediction and Demand 2018 to 2026

Epinephrine
injection is used along with emergency medical treatment to treat
life-threatening allergic reactions caused by insect bites, foods,
medications, and other causes. The epinephrine auto-injectors are
disposable, prefilled automatic injection devices, which are intended
for self-administration of epinephrine solution in an emergency for
on-the-spot treatment during early onset of symptoms of an
anaphylactic reaction.
Market Dynamics
Increasing
prevalence of food allergies is a major factor driving epinephrine
market growth. According to a research conducted by the Centers for
Disease Control and Prevention (CDC) in 2013, in the U.S., from 1997
to 2011, food allergies among children increased around by 50%.
Moreover, according to the European Academy of Allergy and Clinical
Immunology (EAACI), over 17 million people in Europe were affected by
food allergy in 2015. For instance, in November 2017, Kaléo, Inc.
received the FDA approval for its supplemental New Drug Application
(sNDA) for AUVI-Q, the first and only epinephrine auto-injector (EAI)
specifically designed for the treatment of life-threatening allergic
reactions, including anaphylaxis, in infants and small children
weighing 16.5 to 33 pounds.
Increasing
support from government and insurance agencies for generic products
to propel epinephrine market growth
Launch of cost
effective generic epinephrine products by the manufacturers is
majorly attributed to the high price of EpiPen developed by Mylan NV.
The price hike was not accepted by the public, as the drug price
increased to more than 400% over a decade.
According to data
provided by Elsevier Clinical Solutions’ Gold Standard Drug
Database, 2016, the cost of EpiPen was US$ 103.50 in 2009, where the
price increased up to US$ 264.50 in 2013. The price of the product
further increased by 75% costing around US$ 461 in 2015, whereas the
price reached to US$ 608.61 in 2016.
Increase in
prevalence of chronic respiratory diseases to bolster the market
growth
Epinephrine is
available in different doses and concentrations for delivery by
different routes and for different indications, including respiratory
disorders. According to the World Health Organization (WHO), 2018,
Chronic Respiratory Diseases (CRDs) affect more than 1 billion people
worldwide and asthma is a large contributor, affecting children,
adults, and elderly population often throughout their entire lives.
The WHO in 2017, stated that over 300 million patients suffered from
asthma in 2013, and are expected to increase to over 400 million by
2025 globally.
North America
dominates the global epinephrine market, owing to increasing number
of patients suffering from respiratory disease such as asthma. For
instance, according to the Asthma and Allergy Foundation of America,
2014, anaphylaxis is a severe life-threatening allergic reactions
occurring at least 1 in every 50 people in the U.S., and its rate is
as high as 1 in every 20 people.
Ask For Discount
Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/2401
Key Players
Major players
operating in the global epinephrine market include Mylan N.V.,
Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax
Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals Corporation,
Bausch Health Companies, and ALK- Abello A/S.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment